Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

1.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Jul 30. pii: S1470-2045(15)00201-6. doi: 10.1016/S1470-2045(15)00201-6. [Epub ahead of print]

PMID:
26234174
2.

Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.

Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N.

PLoS One. 2015 Jun 24;10(6):e0129022. doi: 10.1371/journal.pone.0129022. eCollection 2015.

3.

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G, Blaise D, Craddock C, Milpied N, Bacher U, Malard F, Esteve J, Nagler A, Mohty M.

Leukemia. 2015 Jun 17. doi: 10.1038/leu.2015.143. [Epub ahead of print]

PMID:
26082270
4.

Nationwide Surveillance of Azole Resistance in Aspergillus Diseases.

Vermeulen E, Maertens J, De Bel A, Nulens E, Boelens J, Surmont I, Mertens A, Boel A, Lagrou K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4569-76. doi: 10.1128/AAC.00233-15. Epub 2015 May 18.

PMID:
25987612
5.

Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.

Vanstraelen K, Maertens J, Augustijns P, Lagrou K, de Loor H, Mols R, Annaert P, Malfroot A, Spriet I.

Clin Pharmacokinet. 2015 Apr 25. [Epub ahead of print]

PMID:
25910879
6.

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J.

Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17.

7.

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study.

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; 3003 Study Group.

Clin Infect Dis. 2015 Aug 1;61(3):313-23. doi: 10.1093/cid/civ287. Epub 2015 Apr 13.

8.

Understanding how different recruitment strategies impact parent engagement with an iPad-based intervention to provide personalized information about adolescent vaccines.

Dempsey AF, Maertens J, Beaty BL, O'Leary ST.

J Adolesc Health. 2015 May;56(5 Suppl):S7-13. doi: 10.1016/j.jadohealth.2014.11.022.

PMID:
25863557
9.

Adapting practice-based intervention research to electronic environments: opportunities and complexities at two institutions.

Stille CJ, Lockhart SA, Maertens JA, Madden CA, Darden PM.

EGEMS (Wash DC). 2015 Feb 10;3(1):1111. doi: 10.13063/2327-9214.1111. eCollection 2015.

10.

Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

Jaspers A, Baron F, Maertens J, De Prijck B, Schots R, Bonnet C, Hafraoui K, Willems É, Servais S, Fillet G, Beguin Y.

Am J Hematol. 2015 Jul;90(7):E133-4. doi: 10.1002/ajh.24013. No abstract available.

PMID:
25802012
11.

Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.

Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, Fillet M, Ory A, Willems E, Gothot A, Humblet-Baron S, Baron F.

Clin Cancer Res. 2015 Jul 15;21(14):3131-9. doi: 10.1158/1078-0432.CCR-14-3374. Epub 2015 Mar 16.

PMID:
25779951
12.

Development of an in vivo glucosylation platform by coupling production to growth: Production of phenolic glucosides by a glycosyltransferase of Vitis vinifera.

De Bruyn F, De Paepe B, Maertens J, Beauprez J, De Cocker P, Mincke S, Stevens C, De Mey M.

Biotechnol Bioeng. 2015 Aug;112(8):1594-603. doi: 10.1002/bit.25570. Epub 2015 Jun 16.

PMID:
25728421
13.

Biotechnological advances in UDP-sugar based glycosylation of small molecules.

De Bruyn F, Maertens J, Beauprez J, Soetaert W, De Mey M.

Biotechnol Adv. 2015 Mar-Apr;33(2):288-302. doi: 10.1016/j.biotechadv.2015.02.005. Epub 2015 Feb 16. Review.

PMID:
25698505
14.

Invasive aspergillosis after kidney transplant: case-control study.

Heylen L, Maertens J, Naesens M, Van Wijngaerden E, Lagrou K, Bammens B, Claes K, Evenepoel P, Meijers B, Kuypers D, Sprangers B.

Clin Infect Dis. 2015 May 15;60(10):1505-11. doi: 10.1093/cid/civ103. Epub 2015 Feb 13.

PMID:
25681376
15.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.

Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonds MP, De Becker A, Beguin Y.

J Hematol Oncol. 2015 Feb 6;8(1):4. doi: 10.1186/s13045-014-0098-9.

16.

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA.

Ann Intern Med. 2015 Jan 20;162(2):81-9. doi: 10.7326/M13-2508. Erratum in: Ann Intern Med. 2015 Mar 17;162(6):463.

PMID:
25599346
17.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.

PMID:
25555450
18.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.

Koenecke C, Göhring G, de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N; MDS subcommittee of the Chronic Malignancies Working Party of the EBMT.

Haematologica. 2015 Mar;100(3):400-8. doi: 10.3324/haematol.2014.116715. Epub 2014 Dec 31.

19.

Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.

Dagklis A, Pauwels D, Lahortiga I, Geerdens E, Bittoun E, Cauwelier B, Tousseyn T, Uyttebroeck A, Maertens J, Verhoef G, Vandenberghe P, Cools J.

Haematologica. 2015 Mar;100(3):e102-5. doi: 10.3324/haematol.2014.119248. Epub 2014 Dec 19. No abstract available.

20.

Key Elements in Determining Voriconazole Protein Binding Characteristics: Comment on "Determination of Plasma Unbound Fraction of Voriconazole in Patients Treated With a Prophylactic or a Curative Treatment".

Vanstraelen K, Pauwels S, Oyaert M, Maertens J, Spriet I.

Ther Drug Monit. 2015 Aug;37(4):551-3. doi: 10.1097/FTD.0000000000000163. No abstract available.

PMID:
25525765
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk